News >

MCL Landscape Rapidly Evolving With Promising Approaches on Horizon

Kristi Rosa
Published: Friday, May 24, 2019

Ann S. LaCasce, MD, MMSc

Ann S. LaCasce, MD, MMSc

Although the FDA approval of ibrutinib (Imbruvica) marked the first major advance in mantle cell lymphoma (MCL) in several years, the emergence of effective agents, such as acalabrutinib (Calquence), venetoclax (Venclexta), bispecific antibodies, and CAR T-cell therapies, has investigators excited for the future, said Ann S. LaCasce, MD, MMSc.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication